Roche joins Pfizer in predicting US tax boost to earnings

Swiss company Roche said US tax cuts will boost profit this year, blunting the impact of competition to the company’s top-selling cancer medicines, and joining rival Pfizer which has reported a boost from US President Donald Trump’s tax overhaul.

Core earnings per share will grow by a percentage in the high single digits, the company said. That compares with a 5% increase last year, when profit fell short of analyst estimates despite some new medicines.